Cost-effectiveness of tumor-treating fields plus standard therapy for advanced non-small cell lung cancer progressed after platinum-based therapy in the United States

Cost-effectiveness of tumor-treating fields plus standard therapy for advanced non-small cell lung cancer progressed after platinum-based therapy in the United States

Background: Tumor treating fields (TTF) was first approved for treatment of glioblastoma. Recently, the LUNAR study demonstrated that TTF + standard therapy (ST) extended survival in patients with advanced non-small cell lung cancer (NSCLC). This primary objective of this study is to analyze the cos...

Full description

Bibliographic Details
Main Authors: Wentao Tian, Jiaoyang Ning, Liu Chen, Yu Zeng, Yin Shi, Gang Xiao, Shuangshuang He, Guilong Tanzhu, Rongrong Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Pharmacology
Subjects:
advanced non-small cell lung cancer
tumor treating fields
immunotherapy
chemotherapy
cost-effectiveness
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1333128/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1333128/full

Similar Items